HCWB

HCW Biologics Inc. is a clinical stage biopharmaceutical company focused on developing first-in-class immunotherapies for autoimmune diseases, cancer, and senescence-associated dysplasia. The company utilizes proprietary drug discovery platforms to create novel fusion immunotherapeutics, including multi-specific cytokines and immune checkpoint inhibitors, which aim to rebalance immune responses and target cancerous cells. HCW Biologics also offers commercial-ready fusion compounds for use as reagents in immunotherapeutic production. Its lead product candidates are advancing through clinical trials and commercialization efforts, with a focus on subcutaneous administration to enhance patient quality of life and reduce costs.